المؤلفون: Sae-Won Han, Jung Hwan Yoon, Seock-Ah Im, Tae-You Kim, Myoung Jin Jang, Tae Yong Kim, Su Jong Yu, Eun Ju Cho, Do-Youn Oh, Yoon Jun Kim, Kyung-Hun Lee, Jeong Hoon Lee, Dae Won Lee

المصدر: British Journal of Cancer

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Carcinoma, Hepatocellular, overall survival, surrogate marker, Antineoplastic Agents, chemotherapy, time to progression, Disease-Free Survival, Statistics, Nonparametric, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Molecular Targeted Therapy, Lung cancer, neoplasms, Proportional Hazards Models, Randomized Controlled Trials as Topic, Surrogate endpoint, business.industry, Proportional hazards model, Liver Neoplasms, Hazard ratio, hepatocellular carcinoma, respiratory system, medicine.disease, Confidence interval, Clinical trial, Treatment Outcome, Clinical Trials, Phase III as Topic, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Meta-analysis, Clinical Study, Disease Progression, Regression Analysis, 030211 gastroenterology & hepatology, business, Biomarkers

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c682e54aa4c0a3778c8880ae09e1d41
https://doi.org/10.1038/bjc.2016.322